Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — |
P/S ratio |
— | — | 0.00 | — |
P/FCF ratio |
— | — | 0.00 | — |
P/Operating CF |
— | — | 0.00 | — |
P/B ratio |
— | — | 0.00 | — |
Price to Tangible BV |
— | — | 0.00 | — |
EV/Sales |
— | — | 0.00 | — |
EV/EBITDA |
— | — | 0.00 | — |
EV/Operating CF |
— | — | 0.00 | — |
EV/FCF |
— | — | 0.00 | — |
Quick Ratio |
1.17 | 8.57 | 0.20 | — |
Current Ratio |
1.37 | 9.56 | 0.76 | — |
Net Debt/EBITDA |
0.02 | 1.07 | (0.09) | — |
Debt/Assets |
64.86% | 18.65% | 10.99% | 0.00% |
Debt/Equity |
(16.55) | 0.26 | (0.10) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.73 | 0.76 | 0.73 | — |
Capex/Depreciation |
(0.43) | (0.66) | (30.73) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | — |
| (221.99%) | (269.24%) | (52.69%) | — | |
| (107.60%) | (140.67%) | (247.19%) | — | |
ROIC |
0.00% | (337.52%) | 0.00% | — |
Return on Tangible Assets |
(783.76%) | (99.35%) | 12,940.98% | — |
Average Days of Receivables |
— | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 45,750.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 33,387.50% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2,912.50% | — |
Graham Net Nets |
— | — | 0.00 | — |
Graham Number |
— | — | 0.00 | — |
Earnings Yield |
— | — | (68.25%) | — |
Free Cash Flow Yield |
— | — | 0.00% | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.23) | (2.37) | (0.58) | — |
Capex per Share |
(0.05) | (0.08) | (0.23) | — |
Free Cash Flow per Share |
(1.28) | (2.46) | (0.81) | — |
Cash per Share |
0.67 | 3.12 | 0.01 | — |
Shareholders Equity per Share |
(0.04) | 2.83 | (0.68) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.04) | 2.83 | (0.68) | — |
Free Cash Flow |
(30.11) | (31.89) | (8.08) | — |
Working Capital |
4.95 | 40.52 | (0.15) | — |
Capital Expenditures |
(1.18) | (1.07) | (2.30) | — |
Net Current Asset Value |
(5.40) | 31.01 | (12.68) | — |
EV/EBIT |
— | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 288.13 | — |
Net Profit Margin |
0.00% | 0.00% | (98,675.00%) | — |
Price to Operating Income |
— | — | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
22.55 | 19.74 | 0.84 | — |
Cash ROIC |
(97.75%) | (35.60%) | 98.82% | — |
Accounts Receivable Turnover |
— | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
0.00 | 0.00 | — | — |
Average Payables |
2.28 | 1.02 | 1.02 | — |
Average Assets |
36.95 | 28.67 | 3.19 | — |
Average Common Equity |
17.91 | 14.98 | 14.98 | — |
Columns are period end dates